News Focus
Gongwin-KY Invited by EIEV in the UAE to Explore PTS Applications in Equine Oncology
Gongwin-KY (6617) advances its Middle East strategy through technical exchange on p-TLS intratumoral tumor ablation for high-value horses ChineseNEWSLINK
Gongwin-KY (6617) was invited by the Emirates International Endurance Village (EIEV) in the United Arab Emirates (UAE) to introduce its proprietary PTS intratumoral chemical ablation technology and exchange perspectives with veterinary professionals on potential applications in equine oncology.
Breakthrough in Pet Cancer Treatment: Gongwin's Novel Canine Melanoma Drug Clears Key Regulatory Milestone
【工商時報記者郭鴻慧台北報導】Gongwin-KY (6617) announced on September 5 that it has received official notification from Taiwan’s Ministry of Agriculture confirming that the technical dossier review for the marketing authorization of its novel targeted tumor ablation drug for the treatment of canine melanoma has been successfully completed. Chinese NEWSLINK
Gongwin-KY's Liver Cancer Therapy Published in International Journal; Phase III Clinical Trial Planned
MoneyDJ News 2026-08-06 10:08:25 Press release article link in Chinese
New Anti-Cancer Weapon Secures U.S. Patent as Gongwin Eyes Global Licensing
Unlike most targeted therapies, Gongwin’s independently developed tumor ablation drug PTS and its related patents have officially received approval from the United States Patent and Trademark Office (USPTO), according to an announcement made early today (August 1). News Link